Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis

Journal of the American College of Cardiology

Volumn 51, Issue 21, 2008, Pages 2028-2033

  Antman, Elliott M ^a   Wiviott, Stephen D ^a   Murphy, Sabina A ^a   Voitk, Juri ^b   Hasin, Yonathan ^c   Widimsky, Petr ^d   Chandna, Harish ^e   Macias, William ^f   McCabe, Carolyn H ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b North Estonian Regional Hospital   (Estonia)

^c The Kittner and Davidai Institute of Cardiology Center   (Israel)

^d CHARLES UNIVERSITY   (Czech Republic)

^e DeTar Hospital   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ARTERY BYPASS; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LONG TERM CARE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; KAPLAN-MEIERS ESTIMATE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, PURINERGIC P2; STENTS; THIOPHENES; TICLOPIDINE;

EID: 43749117048     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.002     Document Type: Article

References (22)

1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007) e1-e157
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) e1-e211
3. King III S.B., Smith Jr. S.C., Hirshfeld Jr. J.W., Jacobs A.K., Morrison D.A., and Williams D.O. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2007 Writing Group to Review New Evidence and Update the 2007 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 51 (2008) 172-209
4. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
5. Gurbel P.A., and Bliden K.P. Durability of platelet inhibition by clopidogrel. Am J Cardiol 91 (2003) 1123-1125
6. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
7. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
8. Jakubowski J.A., Winters K.J., Naganuma H., and Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25 (2007) 357-374
9. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
10. Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635
11. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
12. Anderson J.R., Cain K.C., and Gelber R.D. Analysis of survival by tumor response. J Clin Oncol 1 (1983) 710-719
13. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
14. Payne C.D., Li Y.G., Small D.S., et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50 (2007) 555-562
15. Leong J.Y., Baker R.A., Shah P.J., Cherian V.K., and Knight J.L. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 80 (2005) 928-933
16. Yende S., and Wunderink R.G. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 29 (2001) 2271-2275
17. Szuk T., Gyongyosi M., Homorodi N., et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 153 (2007) 289-295
18. Windecker S., and Meier B. Late coronary stent thrombosis. Circulation 116 (2007) 1952-1965
19. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial. Circulation 116 (2007) 2923-2932
20. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Population Pharmacokinetics, 1999. http://www.fda/gov/cder/guidance/1852fnl.pdf Accessed December 21, 2007
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications, 2003. http://www.fda.gov/cder/guidance/5341fnl.htm Accessed December 21, 2007